Antibiotics 2 Flashcards
Doxycycline
Vibramycin, Doxy 100
Minocycline
Minocin
Amoxicillin
Amoxil, Moxatag
Amoxicillin/Clavulanate
Augmentin
Penicillin
(No brand name listed)
Cephalexin
Keflex, Daxbia
Cefuroxime
Ceftin, Zinacef
Cefdinir
Omnicef
Chlorhexidine
Peridex, Paroex, Hibiclens, Periogard
Doxycycline - Therapeutic Class
Tetracycline Antibiotic
Minocycline - Therapeutic Class
Tetracycline Antibiotic
Amoxicillin - Therapeutic Class
Beta-Lactam Antibiotic
Amoxicillin/Clavulanate - Therapeutic Class
Beta-Lactam Antibiotic
Penicillin - Therapeutic Class
Beta-Lactam Antibiotic
Cephalexin - Therapeutic Class
First-Generation Cephalosporin
Cefuroxime - Therapeutic CLass
Second-Generation Cephalosporin
Cefdinir - Therapeutic Class
Third-Generation Cephalosporin
Doxycycline - Dosage Forms
IR Tablet: 20, 50, 75, 100, 150 mg DR Tablet: 50, 75, 100, 150, 200 mg IR Capsule: 50, 75, 100, 150 mg DR Capsule: 40 mg Oral Suspension: 25 mg/5 mL Oral Syrup: 50 mg/5 mL
Minocycline - Dosage Forms
IR Tablet: 50, 75, 100 mg
ER Tablet: 45, 55, 65, 80, 90, 105, 115, 135 mg
IR Capsule: 50, 75, 100 mg
DR Capsule: 45, 90, 135 mg
Amoxicillin - Dosage Forms
IR Tablet: 500, 875 mg ER Tablet: 775 mg Chewable Tablet: 125, 250 mg Capsule: 250, 500 mg Oral Suspension: 125 mg/5 mL
Amoxicillin/Clavulanate - Dosage Forms
IR Tablet: 250/125, 500/125, 875/125
ER Tablet: 1000/62.5
Chewable Tablet: 200/28.5, 400/57
Oral Suspension (per 5 mL): 125/31.25, 200/28.5, 250/62.5, 400/57, 600/42.9
Penicillin - Dosage Forms
Tablet: 250, 500 mg
Oral Solution: 125 mg/5 mL, 250 mg/5 mL
Cephalexin - Dosage Forms
Tablet: 250, 500 mg
Capsule: 250, 500, 750 mg
Powder for Oral Suspension: 125/5, 250/5
Cefuroxime - Dosage Forms
Tablet: 125, 250, 500 mg
Cefdinir - Dosage Forms
Capsule: 300 mg
Powder for Oral Suspension: 125/5, 250/5
Chlorhexidine - Dosage FOrms
Liquid Oral Rinse: 0.12%
Topical Solution: 2%, 4%
Periodontal Chip: 2.5 mg
Doxycycline - MOA
Broad-spectrum bacteriostatic compound that inhibits protein synthesis at the 30S ribosomal unit
Doxycycline - Activity
Gram (+)
Gram (-)
Aerobic and anaerobic bacteria
Spirochetes, mycoplasmas, rickettsiae, chlamydiae, and some protozoa
Doxycycline - FDA-Approved Indications (Children < 8 years and < 45 kg)
For all three: 2.2-4.4 mg/kg PO in 1-2 divided doses
- Acinetobacter infection
- Acne vulgaris
- Staphylococcal infection of skin
Doxycycline - FDA-Approved Indications (Adults and Children > 8 years and > 45 kg)
- Acinetobacter infection: 100 mg PO q12h, then 100 mg QD
- Acne vulgaris: 100 mg PO q12h on day 1, then 100 mg QD or BID
- Gonorrhea, uncomplicated: 100 mg PO BID x 7 days or 300 mg single dose followed in 1 hour by another 300 mg dose
- Staphylococcal infection of skin: 100 mg PO q12h on day 1, then 100 mg QD
- Pneumonia, community-acquired, empiric therapy: 100 mg PO BID
Doxycycline - Off-Label Uses (Adults and Children >8 years and >45 kg)
- Lyme disease, ppx: 200 mg PO once
- Prosthetic joint infection: 100 mg PO BID in combo w/ rifampin for a minimum of 3 months
- Otitis media, acute: 100 mg PO q12h x 5-7 days
- Cellulitis, mild to moderate: 100 mg PO BID x 5-14 days
Minocycline - MOA
Broad-spectrum bacteriostatic compound that inhibits protein synthesis at the 30S ribosomal unit
Minocycline - Activity
Gram (+)
Gram (-)
Aerobic and anaerobic bacteria
Spirochetes, mycoplasmas, rickettsiae, chlamydiae, and some protozoa
Many bacteria have developed plasmid-mediated resistance
Most Enterobacteriaceae and P. aeruginosa are resistant
Minocycline - FDA-Approved Indications
- Acne vulgaris: Initiate with single 200 mg loading dose, then 100 mg BID (IR); 1 mg/kg/day PO QD for 12 weeks (ER)
- Allergy to penicillin - bacterial infectious disease: initial 200 mg PO, followed by 100 mg PO q12h (adults); 4 mg/kg PO followed by 2 mg/kg/dose q12h (Children >8 years - MDD = 200 mg)
Duration of therapy depends on indication
Amoxicillin - MOA
Semisynthetic penicillin derivative that inhibits the biosynthesis of bacterial cell wall mucopeptide
Amoxicillin - Activity
Streptococcus, Enterococcus, Staphylococcus, Enterobacteriaceae
Amoxicillin - FDA-Approved Indications
- Acute otitis media: 500 mg q8h or 875 mg q12h for 10 days (adults); 80-90 mg/kg/d in 2-3 divided doses (children)
- Lower respiratory tract infection: 1 g TID x 10 days (adults); 45 mg/kg/d divided q12h (children)
- Pharyngitis, tonsilitis: 775 mg QD x 10 days (adults and children >12 years)
- Streptococcal pharyngitis: 500 mg BID or 1 g QD x 10 days (adults); 50 mg/kg QD x 10 days (children - MDD = 1 g)
- Ear, nose, and throat infection, infection of skin and/or subcutaneous tissue, infection of genitourinary system: 500 mg q8h or 875 mg q12 x 5-10 days (adults); 25-45 mg/kg/d divided q12h (children)
- H. pylori GI tract infection: 1 g BID w/ PPI
Amoxicillin - Off-Label Uses
- Bacterial endocarditis, prophylaxis: 2 g PO 1 hour before procedure (adults); 50 mg/kg 1 hour before procedure [MDD = 2 g]
- Lyme disease: 500 mg TID x 14-28 days (adults); 50 mg/kg/d in 3 divided doses x 21-30 days (children)
Amoxicillin/Clavulanate - MOA
Amoxicillin is a semisynthetic penicillin derivative. Amoxicillin is not effective against beta-lactamase-producing bacteria
Clavulanate, a beta-lactamase inhibitor, has weak antibacterial activity but is a potent inhibitor of plasmid-mediated beta-lactamases and protects amoxicillin from degradation by beta-lactamases
Amoxicillin/Clavulanate - Activity
Typically active against Streptococcus, Enterococcus, Staphylococcus, and Enterobacteriaceae
Amoxicillin/Clavulanate - FDA-Approved Indications
- Acute otitis media: 500-875 mg q12h x 10 days (adults); 80-90 mg/kg/d in 2-3 divided doses (children)
- Community-acquired pneumonia: 2000 mg ER BID or 500 mg TID or 875 BID x 5 days (adults)
- Lower respiratory tract infection: 1000 mg TID x 10 days (adults); 45 mg/kg/d divided q12h (children)
- Sinusitis, infection of skin or subcutaneous tissue, infectious disease of genitourinary system: 500-875 mg q8-12h or 2000 mg ER q12h x 5-7 days (adults); 25-45 mg/kg/d divided q12h
- UTI, acute cystitis: 500 mg BID x 5-7 days
- UTI, pyelonephritis: 875 mg BID 10-14 days
Amoxicillin/Clavulanate - Off-Label Uses
- Streptococcal pharyngitis: 875 mg q12h or 500 mg q8h (adults); 45 mg/kg/d divided q12h
- Bite wound prophylaxis and treatment: 875 mg q12h x 3-5 days (prophylaxis); or 5-14 days (treatment)
Penicillin - MOA
Interfere with late stages of bacterial cell wall synthesis
Penicillin - Activity
Active against most Gram (+) organisms and some Gram (-) organisms, notably Neisseria spp.
Resistance is caused by bacterial production of beta-lactamases; some organisms have altered penicillin-binding protein targets (e.g., Enterococci spp. and S. pneumoniae); others have impermeable outer cell wall layers
Penicillin - FDA-Approved Indications
- Bacterial endocarditis, prophylaxis with congenital heart disease or rheumatic/acquired valvular heart disease: 2 g PO 1 h prior to procedure and then 1 g PO 6 h later (adults); 1 g PO 1 h prior to procedure then 500 mg PO 6 h later (children <60 lb)
- Otitis media, mild-moderate, pneumococcal: 250-500 mg q6h until afebrile for at least 2 days (adults); 25-50 mg/kg/d in 3-4 divided doses (children < 12 years; MDD 3 g)
- Streptococcal pharyngitis: 500 mg BID x 10 days (adults); 250 mg BID x 10 days (children <60 lb)
- Erysipelas, mild infection or step-down therapy: 500 mg q6h x 5-10 days
Penicillin - Off-Label Uses
- Pneumococcal infectious disease, prophylaxis in patients with sickle cell disease or asplenia
Children 2 months - 5 years of age: 125 mg PO BID
Children >5 years of age: 250 mg PO BID; discontinue at age 5 y for children who received pneumococcal vaccination and who have not experienced invasive pneumococcal disease